Our network pharmacology analysis demonstrated that mitigating the hyperinflammatory response is a potential mechanism underlying the therapeutic effect of apigenin against COVID-19, potentially implemented through the modulation of the PI3K-Akt and HIF-1 signaling pathways. The gene discussed is AKT1; the disease is COVID-19.